At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

In the mid-1990s, clinicians treating people with HIV began to notice a syndrome characterized by loss of limb fat, facial ...

The owner of the U.S.' largest pharmacy benefit manager is declining to cover Gilead Sciences’ long-acting HIV prevention ...

Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

In people with HIV infection, new-onset diabetes is independently predicted by higher leukocyte counts — mostly within the ...

Analysts lift targets for Gilead as HIV sales surge and Yeztugo launch gains traction, supporting a stronger full-year outlook.

FOSTER CITY, Calif.-- (BUSINESS WIRE)-- #Earnings --Gilead Sciences, Inc. (Nasdaq: GILD) announced today its second quarter 2025 results of operations. “This was a very successful second quarter for ...

Discover key insights from Gilead Sciences' Q2 2025 earnings call, featuring Yeztugo's groundbreaking launch, upward guidance revisions, and strong HIV ...

Gilead Sciences GILD-0.93%decrease; red down pointing triangle raised its guidance for the year after posting better-than-expected results in the second quarter, driven by higher sales from ...

Gilead Sciences reported better second quarter results than Wall Street had expected late Thursday while raising its full-year guidance, but the earnings beat, while reassuring, is largely beside ...